Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17773665 | 0.86 | MEN1 (0.51) | MEN1KMT2AAHRMAPTLMNA | |
| SCHEMBL2226205 | 0.86 | MEN1 (0.60) | MEN1KMT2AAHRMAPTLMNA | |
| Hydrochloric Acid SCHEMBL10559938 | 0.84 | MEN1 (0.58) | MEN1KMT2AAHRMAPTLMNA | |
| SCHEMBL14587559 | 0.84 | MEN1 (0.50) | MEN1KMT2AAHRMAPTLMNA | |
| SCHEMBL14492513 | 0.83 | MEN1 (0.53) | MEN1KMT2AAHRMAPTLMNA | |
| SCHEMBL15598486 | 0.81 | MEN1 (0.47) | MEN1KMT2AAHRMAPTLMNA | |
| SCHEMBL19630932 | 0.81 | MEN1 (0.47) | MEN1KMT2AAHRMAPTLMNA | |
| SCHEMBL5211841 | 0.81 | MEN1 (0.47) | MEN1KMT2AAHRMAPTLMNA | |
| SCHEMBL10559871 | 0.81 | ALDH1A1 (0.45) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL28464641 | 0.81 | MEN1 (0.46) | MEN1KMT2AAHRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551560-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | Huyabio International, LLC (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119707835-A | 2-Aminopyrimidine-5-carboxamide compounds and use thereof for the production of medicaments for the treatment and/or prophylaxis of cancer | 沈阳药科大学 | 2025-03-28 | — | — | CN | disclosed |
| WO-2025017116-A1 | PHARMACEUTICAL COMPOUNDS HAVING ACTIVITY AS WEE1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| WO-2023177591-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| CN-110603256-B | Pyrimidopyrimidinones useful as WEE-1 kinase inhibitors | 阿尔麦克探索有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-20220194947-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-06-02 | — | — | US | disclosed |
| WO-2013059485-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| CN-101671310-A | Compounds and compositions useful as cathepsin s inhibitors | NOVARTIS AG | 2010-03-17 | — | — | CN | disclosed |
| CN-101035768-A | Compounds and compositions as cathepsin S inhibitors | NOVARTIS AG (CH) | 2007-09-12 | — | — | CN | disclosed |
| US-7176310-B1 | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents | UCB SA (GB) | 2007-02-13 | — | — | US | disclosed |
| US-7176310-B1 | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents | UCB SA (GB) | 2007-02-13 | — | — | US | disclosed |
| US-7176310-B1 | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents | UCB SA (GB) | 2007-02-13 | — | — | US | disclosed |
| US-5817669-A | A COMPOUND CONTAINING 1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0787726-A1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | disclosed |
| US-RE32975-E | FUNGICIDES, BACTERICIDES, FEED ADDITIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |
| US-4284629-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | WDR5, WDR1, WDR3 | MEN1 2189/4885KMT2A 44/4885AHR 803/4885 |
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, VHL | MEN1 419/4885KMT2A 2073/4885AHR 559/4885 |
| US-20220194947-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | MEN1 1955/4885KMT2A 1484/4885AHR 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.